CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders.

Neurology
David J IrwinJohn Q Trojanowski

Abstract

To test the association of antemortem CSF biomarkers with postmortem pathology in Lewy body disorders (LBD). Patients with autopsy-confirmed LBD (n = 24) and autopsy-confirmed Alzheimer disease (AD) (n = 23) and cognitively normal (n = 36) controls were studied. In LBD, neuropathologic criteria defined Lewy body α-synuclein (SYN) stages with medium/high AD copathology (SYN + AD = 10) and low/no AD copathology (SYN - AD = 14). Ordinal pathology scores for tau, β-amyloid (Aβ), and SYN pathology were averaged across 7 cortical regions to obtain a global cerebral score for each pathology. CSF total tau (t-tau), phosphorylated tau at threonine181, and Aβ1-42 levels were compared between LBD and control groups and correlated with global cerebral pathology scores in LBD with linear regression. Diagnostic accuracy for postmortem categorization of LBD into SYN + AD vs SYN - AD or neocortical vs brainstem/limbic SYN stage was tested with receiver operating curves. SYN + AD had higher CSF t-tau (mean difference 27.0 ± 8.6 pg/mL) and lower Aβ1-42 (mean difference -84.0 ± 22.9 g/mL) compared to SYN - AD (p < 0.01, both). Increasing global cerebral tau and plaque scores were associated with higher CSF t-tau (R2 = 0.15-0.16, p < 0.05, both) a...Continue Reading

References

Sep 27, 2001·Proceedings of the National Academy of Sciences of the United States of America·E MasliahL Mucke
Apr 17, 2002·Journal of Neural Transmission·K A JellingerW Poewe
Mar 14, 2007·Neurology·C F LippaUNKNOWN DLB/PDD Working Group
Jan 31, 2008·Acta Neuropathologica·Glenda HallidayJohn Morris
Feb 15, 2008·Acta Neuropathologica·Kurt A Jellinger, Johannes Attems
Mar 20, 2009·Annals of Neurology·Leslie M ShawUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Oct 2, 2009·Journal of Neurology·Peter T NelsonWilliam R Markesbery
May 21, 2011·Brain : a Journal of Neurology·Yaroslau ComptaTamas Revesz
Jul 26, 2011·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Sharon X XieJohn Q Trojanowski
Apr 25, 2012·Acta Neuropathologica·Jon B ToledoJohn Q Trojanowski
Jun 14, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·Stephen N GompertsJohn H Growdon
Aug 23, 2012·International Journal of Geriatric Psychiatry·Hans BrunnströmElisabet Englund
Oct 6, 2012·Annals of Neurology·David J IrwinJohn Q Trojanowski
Feb 1, 2013·Journal of Alzheimer's Disease : JAD·Sylvie SlaetsSebastiaan Engelborghs
Feb 15, 2013·JAMA Neurology·Debby TsuangCyrus P Zabetian
Aug 1, 2013·Nature Reviews. Neuroscience·David J IrwinJohn Q Trojanowski
Aug 28, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Jon B ToledoJohn Q Trojanowski
Feb 8, 2014·Nature Medicine·Jing L Guo, Virginia M Y Lee
Jun 23, 2015·Nature Medicine·Teresa BachhuberMelanie Meyer-Luehmann
Sep 4, 2015·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Thomas J MontineBradley T Hyman
Oct 11, 2015·Journal of Neurochemistry·Brit MollenhauerMichael G Schlossmacher
Oct 17, 2015·Movement Disorders : Official Journal of the Movement Disorder Society·Daniela BergGünther Deuschl
Aug 10, 2016·Journal of Geriatric Psychiatry and Neurology·Ian McKeithJoseph Kane
Sep 23, 2016·JAMA Neurology·Stephen N GompertsKeith Johnson
Oct 30, 2016·Journal of Neurology, Neurosurgery, and Psychiatry·A W LemstraS A M Sikkes
Nov 20, 2016·Annals of Neurology·Kejal KantarciRonald C Petersen

❮ Previous
Next ❯

Citations

Sep 12, 2018·Toxicological Sciences : an Official Journal of the Society of Toxicology·Faith L AndersonMatthew C Havrda
Aug 28, 2019·Journal of Parkinson's Disease·Lana M ChahineUNKNOWN The Parkinson’s Progression Markers Initiative
Dec 8, 2019·The Journal of Applied Laboratory Medicine·David J Irwin
Oct 30, 2019·Movement Disorders : Official Journal of the Movement Disorder Society·David G CoughlinDavid J Irwin
Feb 23, 2018·Neurology·David A Bennett, Brian A Gordon
Feb 19, 2020·Expert Review of Molecular Diagnostics·Filippo BaldacciHarald Hampel
May 12, 2019·Journal of Neurochemistry·María-Salud García-AyllónJavier Sáez-Valero
Jun 12, 2019·Bulletin of Experimental Biology and Medicine·V A ZuevV A Pal'tsev
Aug 5, 2020·Nature Biomedical Engineering·Eli J CornblathDanielle S Bassett
Jan 23, 2019·Molecular Neurodegeneration·Tiago Fleming OuteiroIan McKeith
Jun 17, 2020·Annals of Neurology·David J IrwinUNKNOWN Parkinson's Progression Marker Initiative
Oct 5, 2018·Journal of Alzheimer's Disease : JAD·Eleonora FiorenzatoAngelo Antonini
May 21, 2019·Frontiers in Neurology·Tracy R MelzerTim J Anderson
Mar 7, 2019·Biochemical Society Transactions·Shijie Wang, Andrew B West
Oct 28, 2020·Annals of Clinical and Translational Neurology·Nicola SpotornoDavid J Irwin
Dec 16, 2020·Annals of Clinical and Translational Neurology·Lana M ChahineAlex Iranzo
Nov 15, 2020·Journal of Personalized Medicine·Eleonora Del PreteFilippo Baldacci
Feb 4, 2021·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Mélanie BrissonJean-Paul Soucy
Mar 2, 2021·Journal of Alzheimer's Disease : JAD·Sephira G RymanKathleen L Poston
Oct 2, 2020·Neurobiology of Aging·David G CoughlinUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
May 1, 2021·Journal of Neural Transmission·Kurt A Jellinger
Jul 27, 2021·Journal of Alzheimer's Disease : JAD·Sven J van der LeeAfina W Lemstra
Jul 16, 2021·Journal of Neural Transmission·Tommaso SchirinziAntonio Pisani
Jul 22, 2021·Scientific Reports·Min Seok BaekChul Hyoung Lyoo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Researcher Network:CZI Neurodegeneration Challenge

The Neurodegeneration Challenge Network aims to provide funding for and to bring together researchers studying neurodegenerative diseases. Find the latest research from the NDCN grantees here.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.